Viridian Therapeutics reported top-line success from its Phase 3 Reveal-2 program for elegrobart in chronic thyroid eye disease, positioning the company for a U.S. BLA filing in the first quarter of 2027. The trial met both primary endpoints: a proptosis responder rate and an overall responder rate required for U.S. and EMA submissions. Elegrobart is a half-life extended monoclonal antibody against the IGF-1 receptor, delivered subcutaneously via an autoinjector designed for at-home use. If approved, it would compete in a market currently defined by Amgen’s Tepezza (teprotumumab) and a separate in-development Viridian therapy (veligrotug), which is under FDA review. The near-term industry implication is that convenience and dosing design are becoming central differentiators in autoimmune ophthalmology, with late-stage execution increasingly focused on outpatient administration workflows.